CLAIMS

1. A compound which is an agonist of the S1P4 receptor, wherein said compound possesses a selectivity for the S1P4 receptor over one or more of the S1P1, S1P2, S1P3 or S1P5 receptors of at least 10 fold, as measured by the ratio of the EC_{50} of the compound for the S1P4 receptor to the EC_{50} of the compound for the S1P1, S1P2, S1P3 or S1P5 receptor, in free form or in a pharmaceutically acceptable salt form.

2. A compound of formula I



I

wherein

R_1 is phenyl or naphthyl, wherein phenyl is substituted by one or two of halogen, C_{1-6}alkyl, C_{1-6}alkoxy or phenylC_{1-6}alkyl; and

R_2 is hydrogen or C_{1-6}alkyl;

in free, hydrate or salt form.

3. A compound according to claim 1 or claim 2 which is selected from 3-(4-(2-Ethylphenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-benzyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(naphtalen-2-yl)-2-carboxamido-indole)-alanine, 3-(4-(naphtalen-1-yl)-2-carboxamido-indole) -alanine, 3-(4-(2-butoxy-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2-propyl-phenyl)-2-carboxamido-indole)-alanine, 3-(4-(2- isopropyl-phenyl)-2-carboxamido-indole)-alanine and 3-(4-(2,4-dichloro-phenyl)-2-carboxamido-indole)-alanine, or a pharmaceutically acceptable salt therefor.

4. A compound according to claim 3 which is 3-(4-(2-Ethylphenyl)-2-carboxamido-indole)-D-alanine, in free form or in a pharmaceutically acceptable salt form.

5. A compound according to any one of claim 1 to 4, in free form or in a pharmaceutically acceptable salt form, for use as a pharmaceutical.

6. A pharmaceutical composition comprising a compound as defined in any one of claim 1 to 4, in free form or in pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or carrier therefor.

7. Use of a compound according to any one of claim 1 to 4 in free form or in a pharmaceutically acceptable salt form, or a pharmaceutical composition according to claim 4 in the manufacture of a medicament for treating or preventing disorders or diseases mediated by lymphocytes, acute or chronic transplant rejection, T-cell mediated inflammatory or autoimmune diseases, diabetes, allergic diseases, myocarditis, hepatitis, ischemia/reperfusion injury, renal failure, hemorrhage shock, traumatic shock, cancer or infectious diseases.

8. A pharmaceutical combination comprising a compound according to any one of claim 1 to 4 in free form or in a pharmaceutically acceptable salt form and a further agent selected from immunosuppressant, immunomodulatory, anti-inflammatory and chemotherapeutic drug agents.

9. A process for the production of the compound according to claim 2, which process comprises deprotecting a compound of formula II



II

wherein R_1 and R_2 are as defined in claim 2,

R_6 is C_{1-6}alkyl or benzyl,

R_7 is an amino protecting group,

and optionally converting the compound of formula I obtained in free form to a salt form or vice versa.

10. A method for treating or preventing disorders or diseases mediated by lymphocytes, acute or chronic transplant rejection, T-cell mediated inflammatory or autoimmune diseases,

diabetes, allergic diseases, myocarditis, hepatitis, ischemia/reperfusion injury, renal failure, hemorrhage shock, traumatic shock, cancer or infectious diseases, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound according to any one of claim 1 to 4, or a pharmaceutically acceptable salt thereof.